"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer

Clinical trial NCT06067061 · TERMINATED

Trial details

NCT number: NCT06067061
Sponsor: Institut Curie
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Neoplasms

Start date: 2024-04-05
Primary completion: 2025-05-07
Enrollment: 2

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.